[Translation] A single-arm, single-center, non-randomized, open-label Phase I clinical study to evaluate the safety, biodistribution, radiation dose and pharmacokinetics of the novel 18F-labeled Tau protein PET imaging agent XTR006 injection in healthy elderly people

评估新型18F-标记Tau蛋白PET显像剂XTR006注射液在健康成年人中的安全性、生物分布、辐射剂量及药代动力学单臂、单中心、非随机、开放性I期临床研究。

[Translation]

This is a single-arm, single-center, non-randomized, open-label Phase I clinical study to evaluate the safety, biodistribution, radiation dose and pharmacokinetics of the new 18F-labeled Tau protein PET imaging agent XTR006 injection in healthy adults.

Start Date20 Jun 2023

Sponsor / Collaborator

Sinotau Pharmaceutical Group

NCT05464368 / RecruitingPhase 1IIT

Comparison of 18F-RO948, 18F-MK6240, and 18F-GTP1 Radiopharmaceuticals in Patients With Alzheimer Disease and Older Controls

This is an open label study to compare three new generation TAU radioligands, 18F-RO948 (formerly known as 18F-6958948), 18F-MK6240, and [18F]GTP1for imaging of taupathy and demonstrate their absence of off-target binding in patients with Alzheimer disease (AD) and older healthy controls (OC). The study will directly compare AD and OC with these three next-generation TAU radioligands and compare each of them with historical data of the current most widely used first generation radioligand, 18F-AV1451. Upto38 (30 AD (Amyloid +)and 8 OC (Amyloid -), matched for age and sex with A+ subjects) male and female subjects aged 50-100 will be enrolled in this study protocol: up to 8 for Cohort 1, up to 8 for Cohort 2, and up to 22 for Cohort 3. The study consists of three cohorts: Cohort 1: Up to8 AD subjects (A+; CDR 0.5 and 1)will receive two PET scans in random order, with receiving either18F-RO948 or18F-MK6240 at the first scan. A third scan with 18F-GTP1is possible, depending on timing and radiotracer availability Cohort 2:Up to8 OC (A-; CDR=0)subjects will receive two PET scans in random order, with receiving either18F-RO948or 18F-MK6240 at the first scan. A third scan with 18F-GTP1is possible, depending on timing and radiotracer availability Cohort 3:Up to 22 (A+; CDR = 0, .5 and 1) subjects will receive three PET scans in random order, with receiving 18F-RO94818F-MK6240 or18F-GTP1at the first scan. Efforts will be made to include about 1/3 CDR = 0, 1/3 CDR .5, and 1/3 CDR 1 in Cohort 3.

Start Date01 Feb 2023

Sponsor / Collaborator

Washington University School of Medicine

[+1]

NCT04437290 / Not yet recruitingNot ApplicableIIT

University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core

This is a cross-sectional, observational study that characterizes research participants with Alzheimer's disease (AD) for their patterns of brain degeneration with the investigational tau positron emission tomography (PET) radiotracer [18F] MK-6240. The goal is to describe the topographic pattern of involvement of cerebral brain regions (topographic phenotyping) in early stage AD participants using tau PET in a sub-cohort of the University of Washington Alzheimer's Disease Research Center (ADRC) Clinical Cohort, and to make this phenotype information available to affiliated research studies at the University of Washington and to the general scientific community via the National Alzheimer's Coordinating Center.

Start Date01 Nov 2022

Sponsor / Collaborator

University of Washington

[+2]

100 Clinical Results associated with Florquinitau F18

100 Translational Medicine associated with Florquinitau F18

100 Patents (Medical) associated with Florquinitau F18

Literatures (Medical) associated with Florquinitau F18

01 Jun 2024·Acta neuropathologica

Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases

Article

Author: Neelamegam, Ramesh ; Frosch, Matthew P ; Normandin, Marc D ; Gómez-Isla, Teresa ; El Fakhri, Georges ; Dhaynaut, Maeva ; Moon, S-H ; Johnson, Keith ; Kumar, Sunny ; Aguero, Cinthya ; Amaral, Ana C ; Scapellato, Margaret ; Carazo-Casas, Carlos

Abstract:

We and others have shown that [18F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to tau aggregates in Alzheimer's (AD) but has relatively low affinity for tau aggregates in non-AD tauopathies and exhibits off-target binding to neuromelanin- and melanin-containing cells, and to hemorrhages. Several second-generation tau tracers have been subsequently developed. [18F]-MK-6240 and [18F]-PI-2620 are the two that have garnered most attention. Our recent data indicated that the binding pattern of [18F]-MK-6240 closely parallels that of [18F]-Flortaucipir. The present study aimed at the direct comparison of the autoradiographic binding properties and off-target profile of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 in human tissue specimens, and their potential binding to monoamine oxidases (MAO). Phosphor-screen and high resolution autoradiographic patterns of the three tracers were studied in the same postmortem tissue material from AD and non-AD tauopathies, cerebral amyloid angiopathy, synucleopathies, transactive response DNA-binding protein 43 (TDP-43)-frontotemporal lobe degeneration and controls. Our results show that the three tracers show nearly identical autoradiographic binding profiles. They all strongly bind to neurofibrillary tangles in AD but do not seem to bind to a significant extent to tau aggregates in non-AD tauopathies pointing to their limited utility for the in vivo detection of non-AD tau lesions. None of them binds to lesions containing β-amyloid, α-synuclein or TDP-43 but they all show strong off-target binding to neuromelanin and melanin-containing cells, as well as weaker binding to areas of hemorrhage. The autoradiographic binding signals of the three tracers are only weakly displaced by competing concentrations of selective MAO-B inhibitor deprenyl but not by MAO-A inhibitor clorgyline suggesting that MAO enzymes do not appear to be a significant binding target of any of them. These findings provide relevant insights for the correct interpretation of the in vivo behavior of these three tau PET tracers.

01 May 2024·European journal of nuclear medicine and molecular imaging

The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease

Article

Author: Quenon, Lisa ; Hanseeuw, Bernard ; Dricot, Laurence ; Gérard, Thomas ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Colmant, Lise ; Ivanoiu, Adrian ; Lhommel, Renaud

Abstract:

Purpose:

[18F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr).

Methods:

[18F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (Braak ≤ 2, Braak ≤ 4, and Braak ≤ 6) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values.

Results:

The EOT in the Braak ≤ 2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R2 + 0.08–0.09) with the best correlation observed for EOT in the Braak ≤ 4 region (R2 = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values.

Conclusions:

Quantifying [18F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.

22 Jan 2024·Journal of chemical information and modeling

Docking for Molecules That Bind in a Symmetric Stack with SymDOCK

Article

Author: Pepe, Joseph G. ; Shoichet, Brian K. ; Diamond, Marc I. ; Knight, Ian S. ; Shahmoradian, Sarah H. ; DeGrado, William F. ; Irwin, John J. ; Kormos, Rian C. ; Kunach, Peter ; Smith, Matthew S.

Discovering ligands for amyloid fibrils, such as those formed by the tau protein, is an area of great current interest. In recent structures, ligands bind in stacks in the tau fibrils to reflect the rotational and translational symmetry of the fibril itself; in these structures, the ligands make few interactions with the protein but interact extensively with each other. To exploit this symmetry and stacking, we developed SymDOCK, a method to dock molecules that follow the protein's symmetry. For each prospective ligand pose, we apply the symmetry operation of the fibril to generate a self-interacting and fibril-interacting stack, checking that doing so will not cause a clash between the original molecule and its image. Absent a clash, we retain that pose and add the ligand-ligand van der Waals energy to the ligand's docking score (here using DOCK3.8). We can check these geometries and energies using an implementation of ANI, a neural-network-based quantum-mechanical evaluation of the ligand stacking energies. In retrospective calculations, symmetry docking can reproduce the poses of three tau PET tracers whose structures have been determined. More convincingly, in a prospective study, SymDOCK predicted the structure of the PET tracer MK-6240 bound in a symmetrical stack to AD PHF tau before that structure was determined; the docked pose was used to determine how MK-6240 fit the cryo-EM density. In proof-of-concept studies, SymDOCK enriched known ligands over property-matched decoys in retrospective screens without sacrificing docking speed and can address large library screens that seek new symmetrical stackers. Future applications of this approach will be considered.

News (Medical) associated with Florquinitau F18

02 Dec 2024

·www.businesswire.com

Enigma Biomedical USA Announces Formation of Scientific Advisory Board

KNOXVILLE, Tenn.--( BUSINESS WIRE )--Enigma Biomedical USA ( EB USA ) today announced formation of its Scientific Advisory Board ( SAB ), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease. Professor Serge Gauthier of McGill University, Montreal, Quebec, Canada will serve as Chairperson of the EB USA SAB, and will be joined by: Richard Hargreaves Ph.D., Senior Vice President Head of Neuroscience TRC, Bristol Myers Squibb, NJ, Kenji Ishii M.D. , Leader, Team for Neuroimaging Research Tokyo Metropolitan Institute of Gerontology, Japan, Keith Johnson M.D., Ph.D., Director, Molecular Neuroimaging, Department of Radiology Massachusetts General Hospital; Neurologist, Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital; and Professor of Radiology and Neurology, Harvard Medical School, MA, Sterling Johnson Ph.D., Jean R. Finley Professor of Geriatrics and Dementia, Department of Medicine Division of Geriatrics and Gerontology and Principal Investigator, Wisconsin Registry for Alzheimer’s Prevention (WRAP), The University of Wisconsin, WI, Eric M Reiman MD , Executive Director, Banner Alzheimer’s Institute and Chief Executive Officer, Banner Research; Professor of Psychiatry, University of Arizona; University Professor of Neuroscience, Arizona State University; Senior Scientist, Translational Genomics Research Institute; and Director, Arizona Alzheimer’s Consortium, Christopher Rowe FRACP M.D., Director of Molecular Imaging Research and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Australia, Koen Van Laere M.D., Ph.D., D.Sc., Head, Nuclear Medicine and Molecular Imaging, PET-MR Unit, Full Professor, Department of Imaging and Pathology, University Hospital Leuven-KU Leuven, Belgium, and Henrik Zetterberg M.D., Ph.D., Professor/ Chief Physician, Institute for neuroscience and Physiology, University of Gothenburg, Sweden; Group Leader, UK Dementia research Institute, University College London, UK; and Visiting Professor, The University of Wisconsin, WI “We are thrilled to assemble such a remarkably accomplished advisory board, and I am honored to serve as its chairperson. We have a unique mix of complementary expertise from basic sciences to clinical practice that will accelerate knowledge transfer and help persons living with neurodegenerative conditions and their care partners,” said Serge Gauthier, CM, C.Q., M.D., FRCPC, past Director of the McGill University Research Center for Studies in Aging and currently Professor Emeritus in Neurology and Psychiatry and co-lead of the Dementia Education Program at McGill University. “EBG USA greatly appreciates the commitment of these world-class researchers to work with us to advance our mission. We expect this collaboration to yield major strides toward addressing the unmet needs in neurodegenerative disease as well as providing future tools and technologies to support the development of disease modifying therapies,” said Rick Hiatt, President and CEO of EB USA. About Enigma Biomedical – USA Enigma Biomedical USA’s vision is to be the premier provider of imaging biomarkers for neurological pathologies, associated information technology, and related tools to accelerate the development, approval, and adoption of effective therapies to treat neurodegenerative diseases. EB’s neuroimaging biomarkers provide Pharma and Academic researchers with state-of-the-art tools for enabling Disease-Modifying Therapy development with the highest precision and accuracy. In pursuit of this vision, subsidiaries of EB have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts. Both tracers have recently been acquired by a third party for further development. EB also recently announced a partnership with AbbVie to explore their novel 4R Tau PET Imaging Biomarkers.

AcquisitionExecutive Change

20 Nov 2024

·www.businesswire.com

Veravas Completes Analytical Verification Study of the VeraBIND Tau Assay, a Groundbreaking Test to Measure Alzheimer's Tau Pathology in Blood

AUSTIN, Texas--( BUSINESS WIRE )--Veravas, a leading innovator in clinical diagnostics, today announced the results of an analytical verification study of its VeraBIND™ Tau assay, a next-generation test being co-developed with Phanes Biotech, an early-stage biotech company focused on treatments for neurodegenerative diseases, for the detection of Alzheimer’s disease (AD). The test is designed to detect and measure disease pathology to enable the diagnosis of AD at its earliest, most treatable stages. Unlike first-generation tests that measure biomarkers indicative of potential disease, VeraBIND Tau is designed to detect active disease by studying measurable binding activity occurring in the brain between hyperphosphorylated tau (HPT) and normal tau (nTau), which is a hallmark of AD. 1 The test can also aid in the diagnosis of AD, giving clinicians an accessible, accurate, and affordable alternative to tau PET imaging. AD is the sixth leading cause of death in the United States, afflicting an estimated 6.9 million Americans aged 65 or older. 2,3 It’s critical that clinicians have accessible tools to quickly and accurately diagnose and distinguish AD from other dementias causing cognitive impairment to enable targeted treatment. In AD, lifestyle modifications and emerging tau-directed therapies have shown promise in slowing or delaying cognitive decline. Veravas demonstrated VeraBIND Tau’s ability to accurately measure the pathological activity of hyperphosphorylated tau. In this analytical verification study, the test protocol was performed on 100 retrospectively collected patient samples, including 52 confirmed positive for AD tau pathology via F18 MK6240 tau PET imaging (of which, 19 had normal cognitive function, 21 had mild cognitive impairment, and 12 had dementia), 38 healthy controls, and 10 patients positive for beta amyloid plaques but negative by tau PET. 4 The data showed 94.2% sensitivity and 89.6% specificity resulting in an overall VeraBIND Tau assay agreement of 92.0% against tau PET imaging. “These analytical data show that VeraBIND Tau can measure active tau pathology of AD both among individuals with and without cognitive impairment,” said Bernard Hanseeuw, M.D., Ph.D., Associate Head of the Memory Clinic, Neurology Department, Saint Luc University Hospital in Belgium and Instructor at Mass General Hospital, Boston, MA. “The implementation of such a test could not only one day speed the diagnosis of AD, it could also be used to inform the development and testing of tau-directed therapeutics. It also holds great promise for non-AD tauopathies, as the assay proved positive in 7 out of 8 cases tested with low-amyloid, and positive tau-PET data”. To co-develop the VeraBIND Tau assay, the companies used Veravas’s proprietary VeraBIND technology, a platform that is designed to capture and purify key proteins in blood to enable highly accurate protein detection and characterization. When combined with antibodies, VeraBIND magnetic nanobeads act as a filter for multiple sample types, enabling the removal of interfering substances that can obscure the biomarker of interest and potentially produce false results. This patented technology makes it possible to study low-abundance disease-causing proteins that may otherwise be undetectable by enriching samples pre-analytically to improve the detectability of the analyte. “These results demonstrate the transformative potential of VeraBIND Tau to upend the standard of care for management of patients suspected of potentially having Alzheimer’s disease,” said Josh Soldo, Chief Scientific Officer at Veravas. "Our highly accurate analytical test protocol can be performed quickly and cost-effectively and could potentially eliminate both the uncertainties associated with biomarker detection tests and the high costs and wait times associated with tau PET imaging, thereby helping clinicians get answers to their patients much more rapidly.” “The VeraBIND Tau assay will enable Alzheimer’s disease diagnosis for the first time in geographies where tau PET imaging is not available” said Khalid Iqbal, Chief Scientific Officer of Phanes Biotech. For more information about the VeraBIND Tau assay and other VeraBIND products, visit www.veravas.com . About Veravas Veravas is a leading innovator in clinical diagnostics focused on early-stage detection and prognostic screening for Alzheimer’s disease and other neurological conditions. The company’s proprietary VeraBIND™ technology transforms challenging sample types into measurable biomarkers, enabling earlier disease detection and the development of novel diagnostic tests. Its VeraBIND Tau assay is a first-in-class blood-based test that measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment which may be used to aid in the diagnosis of Alzheimer's disease. Learn more at Veravas.com or follow us on LinkedIn . About Phanes Biotech Phanes Biotech is an early-stage biotech company focused on developing breakthrough treatments for neurodegenerative diseases, including Alzheimer’s, macular degeneration, traumatic brain injury, stroke, Down syndrome-associated Alzheimer’s, and cognitive aging. Phanes takes a unique and differentiated approach to Alzheimer’s and other neurodegenerative diseases, setting it apart from existing therapies and drugs currently in development. The company’s pipeline includes innovative drugs: (1) Neuroregenerative small molecule P021 – This promising therapeutic aims to address Alzheimer’s disease by shifting the balance from neurodegeneration toward neural regeneration. (2) Immunotherapy PB43D – A potent, high-affinity antibody designed to target and bind to tau. It is the only antibody shown to reduce both tau and Aβ pathologies. Through a strategic partnership, Phanes leverages its portfolio of tau-targeting antibodies to develop a groundbreaking, first-in-class blood-based assay. This innovative diagnostic tool aims to detect and measure tau pathology activity in the brain, setting a new standard for diagnosing and tracking the progression of Alzheimer’s disease. Learn more at Phanesbiotech.com or follow us on LinkedIn . Thal DR, Tomé SO. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204-217. doi:10.1016/j.brainresbull.2022.10.006 Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement 2024;20(5)." Ahmad FB, Cisewski JA, Anderson RN. Mortality in the United States — Provisional Data, 2023. MMWR Morb Mortal Wkly Rep 2024;73:677–681. DOI: http://dx.doi.org/10.15585/mmwr.mm7331a1 . Gérard T, et al. The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2024 May;51(6):1662-1674.

Clinical ResultImmunotherapy

09 Sep 2024

·www.businesswire.com

Enigma Biomedical - USA Announces Collaboration with Alamar Biosciences to Advance the Field of Diagnostics for Neurodegenerative Diseases

KNOXVILLE, Tenn. & FREMONT, Calif.--( BUSINESS WIRE )--Enigma Biomedical USA (EB) today announced a collaboration with Alamar Biosciences in the field of neurology. Through this collaboration, EB has a non-exclusive right to introduce Alamar’s protein detection and measurement technologies, including its ARGO™ HT instrument and NULISA™ reagent kits, to academic and pharma customers in the field of neurology research. “We are excited to collaborate with Enigma to combine the power of high sensitivity, multiplexed immunoassays with high quality imaging to advance the field of neuro diagnostics,” said Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. This collaboration is designed to yield a large data set of results from neuroimaging and immunoassay from biofluids, which, together, are expected to lead to the development of more efficient diagnostic workflow solutions for patient-centric therapies. Through its affiliate, Enigma Biointelligence (EBI), EB will enable users to order Alamar’s high sensitivity, high specificity immunoassays directly from EBI’s Minerva Bio Platform software. EBI’s Health Grid software will then allow academic and pharma study sponsors to collect, manage and interpret data generated within their studies, including data generated using EB’s PET tracers and the NULISA biofluid based tests. Through this collaboration, EB and Alamar expect to develop analytics products using data generated by shared customers. “Enigma and our affiliate companies are focused on providing information and technologies to researchers and clinicians to improve brain health,” said Rick Hiatt, Chief Executive Officer of Enigma Biomedical USA. “We are thrilled to welcome Alamar to our growing list of first-class partners, who all together share our company’s mission and vision.” “I am confident that the combination of Alamar’s and EBI’s technologies will deliver scalable and accessible diagnostic solutions for patients,” said Dr. Hartmuth Kolb, Chief Scientific Officer of Enigma Biomedical USA. About Enigma Biomedical - USA Enigma Biomedical USA’s vision is to be the premier provider of imaging biomarkers for neurological pathologies, associated information technology, and related tools to accelerate the development, approval, and adoption of effective therapies to treat neurodegenerative diseases. EB’s neuroimaging biomarkers provide Pharma and Academic researchers with state of the art tools for enabling Disease-Modifying Therapy development with the highest precision and accuracy. In pursuit of this vision, subsidiaries of EB have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts. Both tracers have recently been acquired by a third party for further development. EB also recently announced a partnership with AbbVie to explore their novel 4R Tau PET Imaging Biomarkers.

100 Deals associated with Florquinitau F18

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mild cognitive disorder	Phase 3	CN	Sinotau Pharmaceutical Group	01 Nov 2024
Alzheimer Disease	Phase 3	US	University of California	01 May 2018
Cognitive Dysfunction	Phase 3	US	University of California	01 May 2018
Nerve Degeneration	Phase 3	US	University of California	01 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2022	Not Applicable	-	-	[18F]MK6240 (Healthy Controls (CTRL))	aenefdspsi(uxffseeror) = lzeqzgoctt sdaufzhtpp (odifatombs, 0.03) View more	-	08 Aug 2022
				[18F]MK6240 (Mild Cognitive Impairment (MCI))	aenefdspsi(uxffseeror) = bfadbckftk sdaufzhtpp (odifatombs, 0.05)
AAIC2022	Not Applicable	Alzheimer Disease \| disorder of aging	-	18F-MK6240 (Aβ+ve CU)	itnhrnihiq(vnbrvuomhl) = kehhljucxy qwnymcdftq (qnscpchrri ) View more	-	01 Feb 2022
				18F-MK6240 (Aβ+ve CI)	gzuqbzbbtm(phkshpzzrk) = efoftqeqpv zlhxswupfk (ybuiljjabd )
AAIC2020	Not Applicable	-	-	F-18 MK6240 (Ab +ve CN)	vcfhhzyfcp(vjqrtioygp) = aklkqvsgko pxuaupncdk (zhhsrjdzpb )	-	07 Dec 2020
				F-18 MK6240 (MCI)	vcfhhzyfcp(vjqrtioygp) = lpuuyujjgc pxuaupncdk (zhhsrjdzpb )
SNMMI2020	Not Applicable	-	-	MK-6240 ([18F]-MK6240)	ljmiwpmvke(ioxndiqiqa) = jwfyeofwty ncuiyxtgik (tzrqwpzina ) View more	-	15 May 2020
AAIC2019	Not Applicable	-	-	18F-MK-6240 (Amyloid-positive controls with tau pathology)	rkwmbdbdlv(gaixybvqxj) = pkndlogmsm ppmbpnzejv (pywlneuynb )	-	01 Jul 2019
				18F-MK-6240 (Amyloid-positive patients with low tau pathology)	rkwmbdbdlv(gaixybvqxj) = xzxrjttxdo ppmbpnzejv (pywlneuynb )
NCT02562989 (6240-001 \| MK-6240-001, CTgov)	Phase 1	Alzheimer Disease \| Mild cognitive disorder	13	[18F]MK-6240, ~185 MBq (Part 1, Healthy Young Participants)	ebmgnmfzny(zqqvpfumhd) = flbwjgxkyn rzjcgjsbaj (itdkwbupqw, qcpusekwfb - gwfxoatrgb) View more	-	23 Jul 2018
				[18F]MK-6240, ~160 MBq (Part 2, Healthy Elderly Participants)	ebmgnmfzny(zqqvpfumhd) = nluritrxeh rzjcgjsbaj (itdkwbupqw, zxquapyhtk - bzgsuachuz) View more
AAIC2016	Not Applicable	-	-	[18F]MK-6240	gdaogvqdnl(msgityrdlu) = nuphbtzdqk sswxvqmzxg (efxjnnhofe ) View more	-	01 Jul 2016
AAIC2016	Not Applicable	-	-	[18F]MK-6240	zulhitmnmq(jtsbasdfaa) = gotwugplhx lddvxcofma (nyltsfdsjc ) View more	-	01 Jul 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Florquinitau F18

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation